Comments
Drug firm GlaxoSmithKline Pharmaceuticals on Monday reported a 26 per cent rise in its standalone net profit at ₹113 crore for the quarter ended December 31, 2018, mainly on account of one-time gain of ₹28 crore.
The company had posted a net profit of ₹89.69 crore for the corresponding period of the previous fiscal, GlaxoSmithKline Pharmaceuticals said in a filing to BSE.
Standalone revenue from operations of the company stood at ₹825.35 crore for the quarter as against ₹ 703.91 crore for the same period a year ago.
Commenting on the results, GlaxoSmithKline Pharmaceuticals MD A Vaidheesh said, “The business embarked on its new strategy this year, as we put in place an optimal commercial structure and worked at building capability.”
New commercial model of the company is in place, with increased focus on priority brands, and expansion in field force to drive this focus, including a new trade channel strategy, he added.
“Our financial performance highlights the outcomes of this execution with a headline double digit sales growth both for the quarter and year to date, underpinned by a strong volume delivery,” Vaidheesh said.
Exceptional items for the quarter ended December 31, 2018, comprise profit from sale of property of Rs 23 crore and non-core brand divestments contributing Rs 5 crore.”
Shares of GlaxoSmithKline Pharmaceuticals ended at ₹1,402.30 on the BSE, down 0.35 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.